Over 90 firms are actively involved in providing in silico services for drug{RootsAnalysis}

Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads. in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.

To order this 290+ page report, which features 120+ figures and 135+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

The USD 124 million (by 2030) financial opportunity within the in silico drug discovery market for large molecules has been analyzed across the following segments:
 Key Drug Discovery Steps
 Target Identification
 Target Validation
 Hit Generation
 Hit-to-Lead
 Lead Optimization

 Type of Large Molecule
 Antibodies
 Proteins
 Peptides
 Nucleic Acids
 Vectors

 Company Size
 Small
 Mid-sized
 Large

 Target therapeutic Area
 Autoimmune Disorders
 Blood Disorders
 Cardiovascular Disorders
 Gastrointestinal and Digestive Disorders
 Hormonal Disorders
 Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
 Infectious Diseases
 Metabolic Disorders
 Mental Disorders
 Musculoskeletal Disorders
 Neurological Disorders
 Oncological Disorders
 Respiratory Disorders
 Skin Disorders
 Urogenital Disorders
 Others

 Type of Sponsor
 Industry Players
 Non-Industry Players

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific

The In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules, 2020-2030, report

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Leave a Reply

Your email address will not be published. Required fields are marked *